Therefore, our study explored the role of EGFR inhibitors (afatinib and allitinib) and conducted a comprehensive in vitro and in silico analysis of the molecular mechanisms triggered by KRAS mutations in a panel of lung cancer cell lines. This evidence concerns the gene KRAS and lung carcinoma.